Lifeforce, the world’s largest longevity medicine platform, and Toku, a health technology company using AI to translate a single retinal image into real-time biological age and cardiovascular risk scores, have announced a nationwide partnership. The collaboration will turn thousands of routine eye exams each week into powerful opportunities for early health insights and proactive intervention.
The partnership integrates Toku’s BioAge™ wellness product with its forthcoming CLAiR™ technology – a recipient of the prestigious FDA Breakthrough Device designation, which is awarded to technologies that may offer more effective diagnosis or treatment of life-threatening or irreversibly debilitating conditions. CLAiR is currently on an accelerated development path, with anticipated FDA approval in 2026, and aims to transform non-invasive cardiovascular risk assessment using retinal imaging and AI.
Also Read: Athelas Launches AIR: AI-Powered EHR with Ambient Scribing
Through this collaboration, individuals who complete a BioAge analysis – comparing their biological age to their chronological age using a retinal image – will be seamlessly connected to Lifeforce’s comprehensive longevity platform. Lifeforce offers at-home diagnostics, board-certified longevity physicians, personalized protocols, and certified health coaches, enabling participants to take data-driven steps toward extending their healthspan.
“Seeing risk is only half the battle; acting on it is what changes lives,” said Dugal Bain-Kim, Co-Founder and CEO of Lifeforce. “Toku delivers the earliest possible signal, and Lifeforce supplies the clinician guided programs that can slow aging, reduce cardiovascular risk, and extend healthspan.”
“Partnering with Lifeforce ensures that our users are not only empowered with their health data but also supported by an elite, evidence-based longevity care team,” added Ehsan Vaghefi, PhD, CEO and Co-Founder of Toku. “Together, we’re enabling a proactive and accessible approach to lifelong wellbeing.”
Source: PRNewswire
